Lantheus, headquartered in Massachusetts with a global presence, has been a longstanding provider of radiopharmaceutical solutions for over 65 years. Revenue from PYLARIFY, a key product for Lantheus, is anticipated to be in the range of $851 to $853 million, a substantial jump of 61-62  from the prior year's $527.4 million, pending final partner reconciliation. This report is based on a press release statement from Lantheus Holdings, Inc.This article was generated with the support of AI and reviewed by an editor. Excluding this one-time milestone, the company's year-over-year revenue growth is still a robust 37 .Mary Anne Heino, CEO of Lantheus, expressed confidence in the company's performance, attributing the success to the dedication of the Lantheus team and their efforts in advancing the radiopharmaceutical field. BEDFORD, Mass. - Lantheus  NASDAQ LNTH  Holdings, Inc.  NASDAQ  LNTH , a leader in the radiopharmaceutical industry, has reported preliminary unaudited financial results for its fiscal year ended December 31, 2023, indicating significant revenue growth.
Lantheus Holdings, Inc. reported preliminary unaudited financial results for its fiscal year ended December 31, 2023, indicating significant revenue growth. Revenue from PYLARIFY, a key product for Lantheus, is anticipated to be in the range of $851 to $853 million, a substantial jump of 61-62% from the prior year's $527.4 million.